Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study. [PDF]
Adrish M +6 more
europepmc +1 more source
Blood eosinophil count as a biomarker for therapy guidance in COPD and asthma exacerbations. [PDF]
Godallage AN +5 more
europepmc +1 more source
Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis. [PDF]
Mukherjee M +18 more
europepmc +1 more source
Preliminary Effects of Benralizumab in an AML Cell Model with Promyelocytic Features Expressing IL-5R: An Exploratory Proof-of-Concept Study. [PDF]
Piazzetta GL +11 more
europepmc +1 more source
Six-Month Benralizumab Maintenance for Relapsing Chronic Eosinophilic Pneumonia Guided by Eosinophil Kinetics. [PDF]
Sumi T +6 more
europepmc +1 more source
Is allergic sensitization relevant in severe asthma? Which allergens may be culprits? [PDF]
core +1 more source
A Case of Eosinophilic Granulomatosis with Polyangiitis Emerging During Benralizumab Therapy: Successful Management Through a Switch to Mepolizumab Therapy. [PDF]
Saito Y +10 more
europepmc +1 more source
Comment on: Eosinophilic granulomatosis with polyangiitis across the eosinophilic spectrum: from molecular mechanisms to practical differential diagnosis and targeted therapy. [PDF]
Kosałka-Węgiel J, Korkosz M.
europepmc +1 more source

